Juniper Therapeutics Acquires Exclusive Rights for SAR Registration for Anti-Viral COVID-19 Drug from Ping An-Shionogi Hong Kong for Singapore

First drug to show both clinical symptomatic efficacy for five typical Omicron-related symptoms and antiviral efficacy SINGAPORE, Dec. 21, 2023 /PRNewswire/ — Singapore-headquartered Juniper Therapeutix, a science-led healthcare company focused on commercializing novel therapies, today…